How long does it usually take to see significant therapeutic effects from elacestrant?

Elacetrant is a new type of selective estrogen receptor degrader (SERD). It is mainly used to treat estrogen receptor-positive (ER+), HER2-negative advanced or metastatic breast cancer. It is especially suitable for patients who have previously received endocrine therapy and have experienced disease progression. Compared with traditional endocrine therapy, elastran can directly bind to estrogen receptors and promote their degradation, thereby effectively inhibiting the growth and spread of tumor cells. Since its mechanism of action is to gradually affect the growth process of tumor cells, it will not produce an immediate effect in a short period of time, and it usually takes a period of time to evaluate its efficacy.

In clinical practice, it takes approximately 8~12 weeks after most patients start treatment with elastran before a clear treatment response can be observed through imaging examinations or tumor marker testing. This time period is consistent with data from clinical trials such as the EMERALD study. During the trial, researchers will generally conduct the first efficacy evaluation at the 8th week and the 12th week. The changes in tumor volume will be judged through imaging. At the same time, the patient's symptom improvement and condition stabilization will be combined to comprehensively determine whether the drug's efficacy is significant. For patients with slower disease progression, it may sometimes take a longer period (3~4 months) to see clearer efficacy trends.

It should be noted that the efficacy of elastran varies from person to person. Some patients can experience symptom improvement in the early stage of medication, such as bone pain relief, fatigue relief, etc., but the tumor shrinkage may not be obvious on imaging. There are also some patients whose imaging is stable in the early stage of treatment, and then gradually shows obvious tumor shrinkage. For some patients with strong endocrine sensitivity, elastran can even achieve long-term disease control. Therefore, when evaluating the efficacy, we should not only pay attention to the changes in tumor imaging, but also make a comprehensive judgment based on symptoms, signs, and changes in tumor markers.

In addition, clinicians usually recommend that patients maintain regular follow-up visits during treatment and conduct imaging examinations and laboratory tests as planned to understand the efficacy and whether the plan needs to be adjusted in a timely manner. If no obvious effect is seen after 12 weeks, the doctor will evaluate whether to continue treatment or switch to other treatment strategies based on the progression of the disease. Generally speaking, elastran is a drug with a relatively "mild but long-lasting" effect. Significant effects are usually observed after 2 months to 3 months. Therefore, patients need to be patient during the medication and follow the doctor's treatment and monitoring plan.

Reference materials:https://www.drugs.com/